Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospitalisation among adults aged 75-79 years in England
Authors:
- Rebecca SymesRSRebecca Symes
- Heather J WhitakerHWHeather J Whitaker
- Shazaad AhmadSAShazaad Ahmad
- David ArnoldDADavid Arnold
- Suryabrata BanerjeeSBSuryabrata Banerjee
- Cariad M EvansCECariad M Evans
- Robin GoreRGRobin Gore
- Katy HeaneyKHKaty Heaney
- Onn Min KonOKOnn Min Kon
- Anne MelhuishAMAnne Melhuish
- Munira Ortale ZogaibMZMunira Ortale Zogaib
Preprint
Abstract
Background: A respiratory syncytial virus (RSV) vaccination programme for older adults using bivalent pre-F vaccine was introduced in England from September 1, 2024. While vaccine effectiveness has been reported against all-cause RSV-associated respiratory hospitalisations, there are limited data on vaccine effectiveness (VE) against different presentations of RSV-associated illness, such as exacerbation of chronic illness. Methods: We conducted a test-negative design analysis using data from a national, hospital-based acute respiratory infection (ARI) sentinel surveillance (HARISS) system across 14 hospitals in England. From October 1, 2024 to March 31, 2025 vaccine-eligible adults aged 75-79 years hospitalised with ARI for ≥24 hours and tested with molecular diagnostic assays within 48 hours of admission were included. Cases were RSV positive, and controls negative for RSV, influenza and SARS-CoV-2. Vaccination status was obtained from the national registry. Findings: Of 1006 adults hospitalised with ARI, 173 (17.2%) had RSV infection. VE was 82.3% (95%CI:70.6-90.0%) against hospitalisation for any RSV-associated ARI and 86.7% (75.4-93.6%) in those with severe disease including oxygen supplementation. VE was 88.6% (75.6-95.6%) among adults admitted due to lower respiratory tract infection (LRTI), including pneumonia, 77.4% (42.4-92.8%) among adults admitted due to exacerbation of chronic lung disease, and 78.8% (47.8-93.0%) among adults admitted with exacerbation of chronic heart disease, lung disease or frailty. In adults with immunosuppression, VE was 72.8% (39.5-89.3%). Interpretation: This study provides evidence that the RSV pre-F vaccine is highly effective against RSV-associated hospitalisations, including exacerbations of chronic disease and in adults living with immunosuppression. Funding: The UK Health Security Agency.Keywords
This publication has 23 references indexed in Scilit:
- Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or OlderJAMA Network Open, 2025
- Early impact of RSV vaccination in older adults in EnglandThe Lancet, 2025
- Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature ReviewCurrent Allergy and Asthma Reports, 2025
- Early evidence of RSV vaccination impact on hospitalisation rates of older people in ScotlandThe Lancet Infectious Diseases, 2025
- Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation studyThe Lancet Infectious Diseases, 2025
- Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract DiseaseJAMA Network Open, 2024
- Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisThe Lancet, 2024
- RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and OlderJAMA, 2024
- Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in EnglandThe Lancet Regional Health - Europe, 2023
- Respiratory Syncytial Virus and Associations With Cardiovascular Disease in AdultsJACC, 2018